Emerging data on androgen receptor splice variants in prostate cancer
Authors:
- 1 December 2016
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 23 (12) , T199-T210
Abstract
Androgen receptor splice variants are alternatively spliced variants of androgen receptor, which are C-terminally truncated and lack the canonical ligand-binding domain. Accumulating evidence has indicated a significant role of androgen receptor splice variants in mediating resistance of castration-resistant prostate cancer to current therapies and in predicting therapeutic responses. As such, there is an urgent need to target androgen receptor splicing variants for more effective treatment of castration-resistant prostate cancer. Identification of precise and critical targeting points to deactivate androgen receptor splicing variants relies on a deep understanding of how they are generated and the mechanisms of their action. In this review, we will focus on the emerging data on their generation, clinical significance and mechanisms of action as well as the therapeutic influence of these findings.Keywords
This publication has 118 references indexed in Scilit:
- Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer CellsPLOS ONE, 2013
- Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration‐resistant prostate cancerInternational Journal of Cancer, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionOncogene, 2012
- A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancerOncogene, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Phospho‐MED1‐enhanced UBE2C locus looping drives castration‐resistant prostate cancer growthThe EMBO Journal, 2011
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activitiesThe Prostate, 2011
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate CancerCell, 2009